Delivery Order SPE2DB22D3011-SPE2DB25FQ1ZN
- Not listed
- The Defense Logistics Agency awarded a $8,954.00 delivery order to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure with an ultimate completion date of August 15, 2025. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,465.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of August 15, 2025. This non-set-aside competitive award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order is to be fulfilled at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $1,732.55 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with an ultimate completion date of August 11, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- The Defense Logistics Agency awarded a $16,632.48 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $1,386.04 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 15, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial (5ML) on July 25, 2025, with an ultimate completion date of August 15, 2025. This is a non-set-aside contract, competitively awarded to support federal medical procurement needs. The product will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office and primary distribution operations. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,895.75 to AmerisourceBergen Drug Corp for the supply of IMOVAX Rabies Vaccine Vials. The contract, which was competitively awarded with no set-aside designation, is a firm fixed price delivery order with an ultimate completion date of July 21, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,303.22 to AmerisourceBergen Drug Corp for the supply of Rabavert rabies vaccine with diluents. The contract, issued on July 20, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania, supporting the agency's medical supply chain...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ1ZNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 15, 2025, and represents a non-set-aside procurement. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this medical supply delivery. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support platform enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. The company serves federal customers including the Defense Health Agency and U.S. Coast Guard through this flexible contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/27/25 |